4:17 PM ET
8-K
Divestiture
Senti Biosciences Holdings Divestiture to ST NewCo Limited for $60M
Senti Biosciences completed the divestiture of its entire ownership interest in its operating subsidiaries, Midco and Opco, to ST NewCo Limited. In exchange, Senti shareholders will receive contingent value rights (CVRs) entitling them to up to $60.0 million in milestone payments tied to the FDA approval and commercial success of the CAR-NK cell therapy SENTI-202.
- Value
- $60M
- Counterparty
- ST NewCo Limited
- Term
- 7 years